Karger Publishers New Journal – Immune System

Expands Its Open Access Portfolio with an Up-and-Coming Publication for Basic and Applied Immunological Research

Karger Publishers’ new journal Immune System features Open Access-based original research and reviews reporting on translational and clinical studies encompassing all fields of immunology with the intention of bridging clinical research with preclinical and translational investigations. With the launch of this new journal, the company seeks to fulfill a strong need in the scientific community for an open and up-and-coming forum for current basic and applied immunological research. The journal will emphasize evidence-based clinical and laboratory research with statistically valid results that clearly help to advance the future of science.

The world-renowned editors-in-chief, Désirée Larenas-Linnemann, Hospital Medica Sur, Mexico City, Mexico, along with Florent Ginhoux, A*Star, Singapore, are specifically welcoming intra- and interdisciplinary research on Environmental Immunology, Immunomics, Immunotherapy, including but not restricted to immune aspects of allergies, respiratory tract, skin, autoimmune and neurodegenerative disorders. The editors are looking for cutting-edge scientific research, systematic reviews, well-elaborated clinical cases and case-series. The transfer of information from fundamental research to clinical research and clinical practice – that is from lab bench to bed — is particularly welcome.

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann.”

“I’m delighted to announce the launch of our new Karger journal, Immune System, committed to advancing the frontiers of immunology by showcasing and pioneering discoveries that unite clinical and preclinical research. Let’s collaboratively shape a future for immunological research, unbound by limitations” says Marco Casola, Publications Manager of Immunology and Allergy.

Submissions will be accepted on a rolling basis via the journal’s homepage at https://karger.com/ims.

SourceKarger

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”